Download PDF

1. Company Snapshot

1.a. Company Description

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors.It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories.


The company was formerly known as B-D Mérieux.bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France.bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Show Full description

1.b. Last Insights on BIM

bioMérieux's recent performance has been positively driven by several factors. The company launched GENE-UP PRO HRM, a game-changing quality control solution for detecting heat-resistant molds at the molecular level. Additionally, the Saudi Arabia in-vitro diagnostics market, where bioMérieux is a key player, is expected to grow from $734.7M to $932.3M by 2030, driven by a rising elderly population and chronic disease prevalence. Furthermore, bioMérieux's partnership with OhioHealth as a Global Antimicrobial Stewardship Center of Excellence highlights its expertise in antimicrobial stewardship.

1.c. Company Highlights

2. bioMerieux: A Strong Performance with Growth Drivers

bioMerieux reported a robust financial performance, with sales reaching EUR 4 billion, representing a 6.2% organic growth rate, outpacing the market. The company's EBIT margin stood at 17.9% of sales, with a 16% organic growth rate. The EPS came in at EUR 1.99, below analyst estimates of EUR 2.13. The company's cash flow generation reached EUR 460 million, a 40% increase from 2024. The strong performance was driven by the company's four growth drivers: non-respiratory BIOFIRE, SPOTFIRE, Microbiology, and Industrial Applications.

Publication Date: Mar -04

📋 Highlights
  • Revenue & Growth Milestone: Achieved EUR 4 billion in sales with 6.2% organic growth, outpacing market growth.
  • Profitability & Cash Flow: EBIT margin at 17.9% with EUR 460 million cash flow, up 40% YoY.
  • Growth Drivers Expansion: Installed 1,800 BIOFIRE and 6,400 SPOTFIRE units, driving non-respiratory portfolio growth.
  • Regional Performance: North America grew 8% (SPOTFIRE-driven), Latin America surged 18%, and EMEA rose 5%.
  • Future Launches & Guidance: SPOTFIRE aims for EUR 450 million by 2028, with vaginitis panel and hs-cTnI in 2026/2028 pipeline.

Segment Performance

The company's segments performed well, with BIOFIRE and Microbiology growing 5% and 6.3%, respectively, excluding China. North America grew 8% organically, driven by SPOTFIRE's high growth rate, while Latin America delivered a stunning 18% organic growth. The company's gross margin improved by 90 bps, driven by a product mix effect and GO.28 efficiency initiatives.

Guidance and Outlook

For 2026, the company expects to grow between 5% and 7%, with an improvement in EBIT of at least 10%. The non-RP segment is expected to grow around 10%, driven by cross-selling and out-of-US expansion. SPOTFIRE is expected to grow sales by 40% to 60%, in line with the trajectory to reach EUR 450 million by 2028. As Guillaume Bouhours noted, "the company has achieved a 340 basis point organic margin improvement in three years, instead of the targeted five years."

Valuation

Using the current valuation metrics, we can assess what's priced in. The company's P/E Ratio stands at 29.64, indicating a relatively high valuation. The P/S Ratio is 2.9, and the EV/EBITDA is 12.29. The Dividend Yield is 0.9%, and the Free Cash Flow Yield is 3.84%. The ROE is 9.89%, and the ROIC is 6.32%. These metrics suggest that the company's strong growth prospects are already priced in, and investors should carefully consider the risks and opportunities.

3. NewsRoom

Card image cap

BioMerieux SA (BMXMF) Full Year 2025 Earnings Call Highlights: Strong Organic Growth and ...

Feb -27

Source:

Card image cap

Why The Narrative Around bioMérieux (ENXTPA:BIM) Is Shifting As Analysts Rebalance Risk And Growth

Feb -24

Source:

Card image cap

bioMérieux launches SMARTBIOME™ to help food manufacturers gain deeper insights into spoilage and protect product quality

Feb -18

Source:

Card image cap

Commonwealth Fusion Systems Names Stephane Bancel to Board of Directors

Jan -12

Source:

Card image cap

Clinical Microbiology Market Set to Reach USD 7.4 Billion by 2032, Driven by Advancements in Diagnostics and Rising Infectious Disease Rates – SNS Insider

Oct -28

Source:

Card image cap

bioMerieux Product Pipeline and Strategy Analysis Report, 2025

Oct -21

Source:

Card image cap

Should Altesa BioSciences’ Use of SPOTFIRE Shift bioMérieux’s (ENXTPA:BIM) Diagnostic Market Position?

Sep -17

Source:

Card image cap

OhioHealth Partners with bioMérieux as Newest Global Antimicrobial Stewardship Center of Excellence

Aug -26

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.14%)

6. Segments

Clinical Applications

Expected Growth: 8.15%

Strong demand for microbiology and molecular diagnostics, increasing adoption of syndromic testing, and expansion in emerging markets drive bioMérieux's Clinical Applications segment growth. Additionally, the company's strategic acquisitions, innovative product launches, and partnerships with healthcare providers contribute to its 8.15% growth.

Industrial Applications

Expected Growth: 8.1%

Strong demand for industrial microbiology solutions, driven by increasing food safety regulations and growing need for quality control in pharmaceutical and cosmetic industries. bioMérieux's innovative product portfolio, including rapid testing solutions and automated systems, supports this growth. Additionally, strategic partnerships and acquisitions expand the company's presence in emerging markets, further fueling growth.

7. Detailed Products

FilmArray

A molecular diagnostics system that provides rapid and simultaneous detection of multiple pathogens from a single sample

VITEK 2

An automated microbiology system that identifies and provides antibiotic susceptibility testing for bacteria and yeast

VIDAS

A range of immunoassay systems that provide rapid and accurate detection of infectious diseases, such as HIV, HBV, and HCV

API

A range of manual and automated systems for identifying and characterizing microorganisms

INDICAAT

A range of molecular diagnostic tests for infectious diseases, such as tuberculosis and influenza

NucliSENS easyMAG

A molecular diagnostics system that extracts and purifies nucleic acids from clinical samples

8. bioMérieux S.A.'s Porter Forces

Forces Ranking

Threat Of Substitutes

bioMérieux S.A. operates in the in vitro diagnostics industry, which is characterized by a moderate threat of substitutes. While there are alternative diagnostic methods, they are not yet widely adopted, and bioMérieux's products remain a preferred choice for many healthcare professionals.

Bargaining Power Of Customers

bioMérieux S.A.'s customers, primarily healthcare providers and laboratories, have limited bargaining power due to the company's strong brand reputation and the complexity of its products.

Bargaining Power Of Suppliers

bioMérieux S.A. relies on a diverse supplier base, which reduces the bargaining power of individual suppliers. However, the company's dependence on a few critical suppliers for certain components may give them some negotiating power.

Threat Of New Entrants

The in vitro diagnostics industry has high barriers to entry, including significant R&D investments, regulatory hurdles, and the need for established distribution networks, making it challenging for new entrants to compete with bioMérieux S.A.

Intensity Of Rivalry

The in vitro diagnostics industry is highly competitive, with several established players, including Siemens Healthineers, Roche Diagnostics, and Abbott Diagnostics, competing fiercely for market share, which increases the intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 12.15%
Debt Cost 3.95%
Equity Weight 87.85%
Equity Cost 4.69%
WACC 4.60%
Leverage 13.83%

11. Quality Control: bioMérieux S.A. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Recordati

A-Score: 5.8/10

Value: 2.7

Growth: 6.2

Quality: 8.5

Yield: 5.0

Momentum: 4.0

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
bioMérieux

A-Score: 5.0/10

Value: 2.1

Growth: 5.3

Quality: 6.6

Yield: 1.2

Momentum: 6.0

Volatility: 8.7

1-Year Total Return ->

View Full Report
Stock-Card
Qiagen

A-Score: 5.0/10

Value: 2.7

Growth: 4.6

Quality: 7.0

Yield: 4.4

Momentum: 2.5

Volatility: 8.7

1-Year Total Return ->

View Full Report
Stock-Card
Eurofins Scientific

A-Score: 4.8/10

Value: 3.0

Growth: 6.1

Quality: 4.1

Yield: 1.9

Momentum: 7.5

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Synlab

A-Score: 4.2/10

Value: 5.7

Growth: 8.0

Quality: 3.8

Yield: 1.9

Momentum: 4.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
DiaSorin

A-Score: 4.1/10

Value: 4.6

Growth: 5.0

Quality: 7.6

Yield: 2.5

Momentum: 0.0

Volatility: 5.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

91.25$

Current Price

91.25$

Potential

-0.00%

Expected Cash-Flows